Eurofins to invest millions in new UK facility
5800-m2 facility will provide a range of GMP pharmaceutical testing services.
Eurofins Scientific has announced plans to establish a new pharmaceutical chemistry and microbiology facility in Livingston, Scotland as part of a £4 million investment.
The announcement follows Eurofins’ acquisition of Exova’s pharmaceutical, food and water testing business in the UK & Ireland in July 2016, and the subsequent purchase of ILS’s pharmaceutical business in October 2016.
Significantly increasing its capacity in the UK, the 5800-m2 facility at Brucefield Industry Park will house Eurofins’ biopharmaceutical testing business in the UK, currently based in Edinburgh. The first phase of the project will see the development of 1400 m2 of lab space and creates the scope for significant expansion.
Alison Clayton, general manager at Eurofins BioPharma Product Testing commented: “It’s an exciting time for Eurofins as we strengthen our footprint in the UK and Ireland. The new facility offers significant capacity for future growth, as well as the space to take on new projects more rapidly and react to customer needs more flexibly.
“The purpose-built lab space will also help to improve productivity, meaning we can provide a more streamlined and efficient service to biopharmaceutical companies accessing our analytical testing services.
“From the new facility, Eurofins BioPharma Product Testing UK will provide a range of GMP pharmaceutical testing services, including, but not exclusively method development and validation, finished product and raw material testing, elemental impurity testing, micro testing and stability studies.”
As part of the investment, Eurofins BioPharma Product Testing UK will be purchasing a new inductively coupled plasma mass spectrometry (ICP-MS) machine, enabling the company to meet growing demand for this service. Eurofins will also invest in more high-performance liquid chromatography (HPLC) equipment, increasing its capacity by 40%.
Alison continued: “At Eurofins BioPharma Product Testing UK, we are committed to adapting and growing our offering in line with customers’ evolving needs. Following the introduction of the International Conference on Harmonization (ICH), Q3D Guideline for Elemental Impurities relating to existing drug products in the US and Europe, we have seen greater demand for more quantitative methods of elemental analysis such as the use of ICP-MS technology.
“From the 1st January 2018, these regulations will apply to both new and existing drug products, so by investing now, we are preparing for future demand and market requirements.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance